Bibliography
- WHITE AD et al.: Emerging therapeutic advances for the development of second generation matrix metallopro-teinase inhibitors. Curr. Pharm. Design (1997) 3:45–58.
- ZASK A, LEVIN JI et al.: Inhibition of matrix metallopro-teinases: structure based design. Curr. Pharm. Design (1996) 2:624–661.
- DAVIDSEN SK, SUMMERS JB: Inhibitors of TNF-a synthe-sis. Exp. Opin. Ther. Patents (1995) 5:1087–1100.
- DAVIDSON AH, DRUMMOND AH et al.: The inhibition ofmatrix metalloproteinase enzymes. Chem. Ind. (1997) 258–261.
- WOOD ND, AITKEN M et al.: The tolerability and phar-macokinetics of the cartilage protective agent (RO 32–3555) in healthy male volunteers. British Pharmacologi-cal Society Summer Meeting, Bath, UK (1996). Poster P234.
- MACPHERSON LJ et al.: Discovery of CGS 27023A, a non-peptidic, potent and orally active stromelysin inhibi-tor that blocks cartilage degradation in rabbits. J. Med. Chem. (1997) 40:2525–2532.
- LEVITT NC et al.: A phase one pharmacokinetic study of CGS27023A, A matrix metalloproteinase inhibitor. 34th Annual Meeting of the American Society Clinical On-cology. Los Angeles, USA (1998). Abstract 213a.
- COLLIER MA, YUEN GJ et al.: A Phase I study of the ma-trix metalloproteinase (MMP) inhibitor AG 3340 given in single doses to healthy volunteers. All CR Meeting San Diego, USA (1997). Poster 1491.
- GROCHOW L et al.: Phase land pharmacokinetic study of the matrix metalloproteinase Inhibitor (MMPO BAY 12–9566. 34th Annual Meeting of the American Society Clinical Oncology. Los Angeles, USA (1998). Abstract 822.
- SZARDENINGS AK et al.: Rational design and combina-torial evaluation of enzyme inhibitor scaffolds: identi-fication of novel inhibitors of matrix metalloproteinases. J. Med. Chem. (1998) 41:2194–2200.
- ••Describes and analyses compounds covered in this patentapplication.
- SZARDENINGS AK et al.: A simple procedure for thesolid-phase synthesis of diketopiperazine and diketo-morpholine derivatives. Tetrahedron (1997) 53:6573–6593.
- WOJTOWICH-PRAGE S et al: Phase I trial of marimastat,a novel matrix metalloproteinase inhibitor, adminis-tered orally to patients with advanced lung cancer. J. Clin. Oncol. (1998) 16(6):2150–2156.